(Q43784343)

26 November 2017

title

Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation (English)

1 reference

26 November 2017

1 reference

1 reference

S Giambartolomei

1

1 reference

26 November 2017

M Artini

2

1 reference

26 November 2017

C Almerighi

3

1 reference

26 November 2017

S M Moavero

4

1 reference

26 November 2017

M Levrero

5

1 reference

26 November 2017

C Balsano

6

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

26 November 2017

1 reference

26 November 2017

volume

30

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

510-516

1 reference

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Therapy of hepatitis C: alpha interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Interferon-α therapy combined with nonsteroid antiinflammatory drugs for treatment of chronic viral hepatitis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Activation of mitogen-activated protein kinase by arachidonic acid in rat liver epithelial WB cells by a protein kinase C-dependent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Quantitative analysis of interferon alpha/beta receptor mRNA in the liver of patients with chronic hepatitis C: correlation with serum hepatitis C virus-RNA levels and response to treatment with interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Signal transduction by interferon-alpha through arachidonic acid metabolism

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300224

7 January 2021

Identifiers

DOI

10.1002/HEP.510300224

1 reference

26 November 2017

1 reference